

## **Oncopeptides publishes the 2023 Annual Report**

**Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2023 Annual Report has been published.**

"2023 was a year when we set ourselves up for success in Europe. We built the foundation in Germany where we now have a full team in place and have secured a price that reflects our scientific innovation. This was a critical achievement to ensure a reference price point for the rest of Europe where we during the year worked intensively to progress market access," says Sofia Heigis, CEO of Oncopeptides. "Commercializing a new drug doesn't happen overnight, but I am fully convinced that we are on the right track and that we slowly but surely have started to gain speed."

The Annual Report for 2023 is available in PDF format at Oncopeptides' web site under [financial reports](#).

### **For more information, please contact:**

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: [david.augustsson@oncopeptides.com](mailto:david.augustsson@oncopeptides.com)

Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-22 19:45 CEST.

### **About Oncopeptides**

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination



with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information see: [www.oncopeptides.com](http://www.oncopeptides.com).